Back to results
US 2006/0135443 A1Published application
Use of Na*/K*-ATPase inhibitors and antagonists thereof
AssigneeBionaut Pharmaceuticals, Inc.
InventorsMehran Khodadoust, Ajay Sharma
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBionaut Pharmaceuticals, Inc.
InventorsMehran Khodadoust, Ajay Sharma
Estimating the term…
The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating hypoxia-related pathological conditions, such as Alzheimer's Disease, and those involving excessive angiogenesis, especially those non-cancer pathological conditions. The invention provides the use of Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents for treating such conditions. The invention also relates to the use of cardiac glycoside inhibitors/antagonists as reagents, pharmaceutical formulations, or in kits and methods for treating conditions arising from excessive amount of cardiac glycosides, including all symptoms of digitalis poisoning, depression, hypertension, etc. The pharmaceutical formulation of the invention may be delivered to a patient either systemically or locally, or both. The pharmaceutical formulations of the invention may be delivered either in one dose, or continuously over a sustained period of time using, for example, sustained drug delivery devices.
A pharmaceutical formulation comprising a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-angiogenesis agent, formulated in a pharmaceutically acceptable excipient and suitable for use in human patients to reduce angiogenesis.
A kit for treating a patient having excessive or undesirable angiogenesis, comprising a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-angiogenesis agent, formulated in premeasured doses for conjoint administration to said patient.
A method for treating a patient having excessive or undesirable angiogenesis, comprising administering to the patient an effective amount of a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-angiogenesis agent.
A method for promoting treatment of patients having excessive or undesirable angiogenesis, comprising packaging, labeling and/or marketing a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-angiogenesis agent, for use in therapy or conjoint therapy for treating said patients.
A method for promoting treatment of patients having excessive or undesirable angiogenesis, comprising packaging, labeling and/or marketing an anti-angiogenesis agent to be used in conjoint therapy with a Na+/K+-ATPase inhibitor for treating the patients.
A method to treat Rheumatoid Arthritis (RA) in a patient, comprising administering to synovial tissue of a bone joint of the patient a composition containing a Na+/K+-ATPase inhibitor, such as a cardiac glycoside agonist (e.g. ouabain or proscillaridin, etc.), at an amount/level sufficient to down-regulate VEGF expression in synovial tissue and inhibit angiogenesis in the synovial tissue.
A method to treat diabetic retinopathy in a patient, comprising administering to a retina of the patient a composition containing a Na+/K+-ATPase inhibitor, such as a cardiac glycoside agonist (e.g. ouabain or proscillaridin, etc.), at an amount/level sufficient to down-regulate VEGF expression in the retina and inhibit angiogenesis in the retina.
A method to treat choroidal neovascularization in a patient, comprising delivering to subretinal space or retinal pigment epithelium of the patient a composition containing a Na+/K+-ATPase inhibitor, such as a cardiac glycoside agonist (e.g. ouabain or proscillaridin, etc.), at an amount/level sufficient to down-regulate VEGF expression in said tissue and inhibit angiogenesis in the choroidal tissue.
A pharmaceutical formulation comprising a Na+/K+-ATPase inhibitor, either alone or in combination with an agent effective for treating or preventing Alzheimer's Disease (AD), formulated in a pharmaceutically acceptable excipient and suitable for use in human patients to treat or prevent AD.
A pharmaceutical formulation comprising an antagonist of a Na+/K+-ATPase inhibitor, either alone or in combination with an anti-depression agent, formulated in a pharmaceutically acceptable excipient and suitable for use in human patients to reduce depression.
A pharmaceutical formulation comprising an antagonist of a Na+/K+-ATPase inhibitor formulated in a pharmaceutically acceptable excipient and suitable for use in human patients to treat digitalis poinsoning.
Dependencies are inferred from the claim text.